Pneumonia Vaccines Market Projected to Reach USD 15.46 Billion by 2030 with a CAGR of 6%

Pneumonia Vaccines Market Projected to Reach USD 15.46 Billion by 2030 with a CAGR of 6%

According to Next Move Strategy Consulting, the global Pneumonia Vaccines Market is set to experience significant growth, with a projected value of USD 15 billion by 2030. This represents a Compound Annual Growth Rate (CAGR) of 7% during the forecast period by 2030.

Download Free Sample: https://www.nextmsc.com/pneumonia-vaccines-market/request-sample

Market Overview

Pneumonia vaccines are vital in protecting both pediatric and adult populations against pneumococcal bacterial strains by stimulating the immune system. These vaccines play a critical role in preventing the spread of pneumonia, minimizing hospitalization rates, and reducing fatalities. The global demand for pneumonia vaccines is driven by the high burden of pneumonia cases worldwide, which affect approximately 450 million people annually and result in 4 million deaths. With a growing prevalence of pneumococcal infections and rising awareness, the market for pneumonia vaccines is witnessing substantial growth.

There are two primary types of pneumonia vaccines currently available in the market: Pneumococcal Polysaccharide Vaccine (PPSV23), which targets 23 types of pneumococcal bacteria, and Pneumococcal Conjugate Vaccine (PCV13), which protects against 13 strains. These vaccines are integral in reducing the incidence and severity of pneumonia, particularly in vulnerable populations, such as young children and the elderly.

Market Dynamics and Trends

Governmental and non-governmental organizations worldwide, including UNICEF, GAVI, and the WHO, are focusing heavily on pneumonia vaccination campaigns, which further bolster market growth. Notably, the Atlantic Health Partners added Prevnar 13 to its vaccine program in December 2020, enabling better access to this crucial vaccine.

The market is also benefiting from a rising number of awareness campaigns and increased funding for pneumonia prevention, particularly in regions such as India, Nigeria, and Ethiopia, where the disease burden remains high.

Inquire Before Buying: https://www.nextmsc.com/pneumonia-vaccines-market/inquire-before-buying

Challenges and Opportunities

While the market is expanding, challenges such as high vaccine production costs and stringent approval processes remain. However, innovations in protein-based vaccines, such as the development of PhtD monovalent and PhtD+dPly vaccines, are expected to drive future growth and offer lucrative opportunities for market participants.

Market Segmentation

The global pneumonia vaccines market is segmented by type, product, sector, distribution channel, and age group:

  • Type: Pneumococcal Conjugate Vaccine, Pneumococcal Polysaccharide Vaccine
  • Product: Prevnar 13, Synflorix, Pneumovax 23, Others
  • Sector: Public Sector, Private Sector
  • Age Group: Pediatric, Adult
  • Distribution Channel: Distribution Partners, NGOs, Public Health Agencies, Community Clinics
  • Geography: North America, Europe, Asia-Pacific, and Rest of the World

Regional Analysis

North America is expected to lead the market in terms of revenue due to advanced healthcare infrastructure, high prevalence of pneumonia, and substantial research funding. For instance, the National Institutes of Health allocated approximately USD 660 million for pneumonia and influenza research between FY 2013 and 2020. Additionally, several U.S.-based companies, including Merck and Pfizer, are making significant strides in vaccine development, such as the FDA-approved Prevnar 20 and VAXNEUVANCE vaccines.

Asia-Pacific is anticipated to exhibit significant growth due to increasing cases of malnutrition and strategies implemented by public health organizations, such as India’s expansion of pneumonia vaccines under its universal immunization program.

Competitive Landscape

Key players in the global pneumonia vaccines market include GlaxoSmithKline plc., LG Chem Ltd., Merck & Co., Inc., Panacea Biotec Limited, Pfizer Inc., Pnuvax Incorporated, Serum Institute of India Pvt. Ltd., Astellas Pharma Inc., SK Bioscience, and Walvax Biotechnology Co., Ltd. These companies are investing in research and development to introduce new and improved products. Notably, Pfizer’s PREVNAR 20 received FDA approval in June 2021, and Merck’s VAXNEUVANCE received FDA approval in July 2021.

Conclusion

The pneumonia vaccines market is on a strong growth trajectory, driven by increasing awareness, global vaccination efforts, and ongoing innovation in vaccine development. With rising cases of pneumonia, particularly among vulnerable populations, the demand for pneumonia vaccines is set to soar in the coming years.

Also, Browse Related Reports:   

For more information, please contact:

Next Move Strategy Consulting

E-Mail: info@nextmsc.com

Direct: +1-217-650-7991

Website: www.nextmsc.com

Follow Us: LinkedIn | Twitter | Facebook | Instagram | YouTube

About Next Move Strategy Consulting:

Next Move Strategy Consulting is a premier market research and management consulting firm that has been committed to provide strategically analysed well documented latest research reports to its clients. The research industry is flooded with many firms to choose from, what makes Next Move different from the rest is its top-quality research and the obsession of turning data into knowledge by dissecting every bit of it and providing fact-based research recommendation that is supported by information collected from over 500 million websites, paid databases, industry journals and one on one consultations with industry experts across a diverse range of industry sectors. The high-quality customized research reports with actionable insights and excellent end-to-end customer service help our clients to take critical business decisions that enables them to move beyond time and have competitive edge in the industry.

We have been servicing over 1000 customers globally that includes 90% of the Fortune 500 companies over a decade. Our analysts are constantly tracking various high growth markets and identifying hidden opportunities in each sector or the industry. We provide one of the industry’s best quality syndicates as well as custom research reports across 10 different industry verticals. We are committed to deliver high quality research solutions in accordance to your business needs. Our industry standard delivery solutions that range from the pre consultation to after-sales services, provide an excellent client experience and ensure right strategic decision making for businesses.

Back to blog